Entheon Biomedical Corp
CNSX:ENBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (6.7), the stock would be worth CA$-0.15 (254% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.3 | CA$0.1 |
0%
|
| Industry Average | 6.7 | CA$-0.15 |
-254%
|
| Country Average | 11.9 | CA$-0.28 |
-375%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
E
|
Entheon Biomedical Corp
CNSX:ENBI
|
1.4m CAD | -4.3 | -5 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 45 425.5 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.4B ZAR | 18.1 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.5B USD | -46 271.6 | 38 690 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.6B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 39.7 | -3 284.6 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 17.8 | 174.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.1B ZAR | 17.4 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.9 |
| Median | 11.9 |
| 70th Percentile | 19.5 |
| Max | 22 577.3 |
Other Multiples
Entheon Biomedical Corp
Glance View
Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.
